NDAORALSOLUTION
Approved
Mar 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
3
Data completeness
6/8 — Strong
HEMANGEOL (propranolol hydrochloride) by Pierre Fabre is hemangeol's effects on infantile hemangiomas is not well understood. First approved in 2014.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMANGEOL is an oral propranolol hydrochloride solution approved for infantile hemangiomas, a common benign vascular tumor in infants. The mechanism of action is not fully understood, but propranolol is believed to induce vasoconstriction and inhibit angiogenesis. It represents the first FDA-approved systemic therapy for this indication.
$13KPart D
LOE ApproachingDeclining
1.9 years to LOEProduct is in late-stage commercialization with minimal Part D spending ($13K in 2023), indicating a niche indication with limited patient volume and declining team investment.
Mechanism of Action
HEMANGEOL's effects on infantile hemangiomas is not well understood.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Started Nov 2024
6 enrolled
Non Small Cell Lung CancerPropranolol
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Started Sep 2005
100 enrolled
Healthy
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Started Sep 2005
98 enrolled
Healthy
Why This Matters for Your Career
Worked on HEMANGEOL at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.